HORSHOLM, Denmark, Feb. 11, 2011 /PRNewswire/ -- LifeCycle Pharma A/S (OMX: LCP) today announced that William J. Polvino, M.D., president and chief executive officer, will present at the 13th Annual BIO CEO & Investor Conference at 10:30 a.m. EST, February 14, 2011, at the Waldorf-Astoria Hotel in New York City. Dr. Polvino will provide an overview of the company and its lead Phase 3 candidate to prevent organ transplant rejection, LCP-Tacro.
For U.S. investor and media contacts: | |
John Weinberg, M.D., Senior VP, Commercial Development and Strategic Planning | |
LifeCycle Pharma A/S | |
(732) 321-3208 | |
jdw@lcpharma.com | |
About LifeCycle Pharma A/S (LCP)
Based in Horsholm, Denmark, with an office in New Jersey, LCP is a specialty pharmaceutical company. Clinical development is the core of LCP’s efforts to develop a product portfolio which includes the Company’s lead product candidate, LCP-Tacro, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. LCP adapts new technologies on a fast commercial timetable. LCP’s unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability - at low-scale up costs - not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: LCP.
For further information, please visit www.lcpharma.com.
SOURCE LifeCycle Pharma A/S
